Zepbound is the best proven pick.
The best GLP-1 for weight loss is usually Zepbound for maximum average weight loss, Wegovy HD if you want the strongest semaglutide option, Wegovy 2.4 mg if you want the most established single-agonist GLP-1, and oral options if avoiding injections matters more than chasing the highest trial number.
🔑 Key Takeaways
- Zepbound ranks first because tirzepatide beat semaglutide directly in SURMOUNT-5: 20.2% vs 13.7% average body-weight loss at 72 weeks.
- Wegovy HD changes the old comparison. The 7.2 mg semaglutide dose was cleared in March 2026 and reported about 20.7% mean weight loss in STEP UP under the adherent estimand.
- Wegovy 2.4 mg is still the most established single-agonist GLP-1 obesity injection, with about 14.9% average loss in STEP 1.
- Wegovy pill and Foundayo now make oral GLP-1 weight loss real, but convenience and weight-loss power are not the same thing.
- Saxenda is older, daily, and usually weaker. It still matters when coverage, tolerability, or pediatric prescribing makes it the practical option.
This page is built from the top-ranking comparison intent: rank the options, explain the data, separate brand names from active ingredients, cover cost and access, and make the next decision obvious.
Best GLP-1 for Weight Loss: The Ranking
The ranking starts with outcomes.
Most articles stop at Ozempic, Wegovy, Mounjaro, and Zepbound. That is no longer enough. As of May 1, 2026, the practical comparison also needs Wegovy HD, the Wegovy pill, and Foundayo.
| Rank | Best Fit | Medication | Active Ingredient | Typical Result | Main Limitation |
|---|---|---|---|---|---|
| 1 | Maximum proven weight loss | Zepbound | Tirzepatide | 20.2% in SURMOUNT-5 vs Wegovy 2.4 mg | Injection, supply, coverage, GI effects |
| 2 | Strongest semaglutide injection | Wegovy HD | Semaglutide 7.2 mg | About 20.7% reported in STEP UP under adherent analysis | Newer dose, no head-to-head vs Zepbound yet |
| 3 | Established GLP-1 obesity care | Wegovy | Semaglutide 2.4 mg | 14.9% in STEP 1 | Less weight loss than tirzepatide |
| 4 | Best needle-free semaglutide | Wegovy pill | Oral semaglutide 25 mg | About 16.6% if all stayed on treatment in OASIS 4 | Daily pill with fasting rules |
| 5 | Easiest oral routine | Foundayo | Orforglipron | 12.4% at highest dose in ATTAIN-1 | Lower average loss than top injections |
| 6 | Older daily option | Saxenda | Liraglutide 3 mg | About 8% in a large trial | Daily injection and weaker results |
Plain answer
If the question is “which GLP-1 produces the most proven weight loss,” choose Zepbound. If the question is “which GLP-1 fits my life,” the answer may change because cost, access, nausea, injection comfort, and long-term adherence decide the real result.
Why Zepbound Ranks First
The direct trial matters.
Zepbound is the obesity brand name for tirzepatide. Mounjaro uses the same active ingredient for type 2 diabetes. Tirzepatide is often called a GLP-1 in casual search results, but it is technically a dual GIP and GLP-1 receptor agonist. That dual action is why it sits at the top of most current weight-loss comparisons.
In SURMOUNT-5, tirzepatide was tested directly against semaglutide in adults with obesity but without type 2 diabetes. At 72 weeks, tirzepatide produced 20.2% average weight loss versus 13.7% with semaglutide. The same trial also favored tirzepatide on larger weight-loss thresholds: more people lost at least 15%, 20%, and 25% of body weight.
That does not make Zepbound perfect. It is still an injection. Nausea, diarrhea, constipation, vomiting, reflux, gallbladder problems, and dehydration risk can all show up. Coverage can be difficult. Supply can still be annoying. But if the reader is asking for the strongest proven GLP-1-style option, Zepbound is the answer.
Wegovy HD Changes the Old Answer
Semaglutide caught up somewhat.
For years, the simple comparison was Zepbound around 20% and Wegovy around 15%. Wegovy HD makes that older framing incomplete. The new 7.2 mg semaglutide injection was cleared by the FDA on March 19, 2026 for adults with obesity or overweight with at least one weight-related condition.
Novo Nordisk reported 20.7% mean weight loss in the STEP UP program under the adherent analysis. That puts high-dose semaglutide much closer to tirzepatide on headline efficacy than old Wegovy 2.4 mg.
The caveat is important: Wegovy HD has not replaced the direct Zepbound vs Wegovy evidence. It is a newer high-dose semaglutide option with strong trial data, but it has not beaten tirzepatide in a direct published obesity head-to-head. That is why it ranks second here, not first.
Wegovy 2.4 mg Still Matters
Established access matters too.
Wegovy 2.4 mg is the older injectable semaglutide obesity dose. It is not the strongest average weight-loss option anymore, but it remains one of the best-studied and most recognizable GLP-1 choices.
In STEP 1, semaglutide 2.4 mg produced about 14.9% average weight loss at 68 weeks when paired with lifestyle intervention. For many people, that is still a life-changing result. It is also the reason Ozempic became such a common off-label weight-loss conversation: same molecule, different labeled use and dose strategy.
Wegovy may be the better fit when insurance prefers semaglutide, when a patient has already tolerated it, when cardiovascular-risk labeling matters, or when a clinician wants a familiar GLP-1 before moving to newer or stronger options.
Oral GLP-1 Options Are Now Real
Needles are no longer mandatory.
Two oral options changed the conversation: Wegovy pill and Foundayo. They solve different problems.
| Oral Option | Active Ingredient | Why It Matters | Weight-Loss Context | Main Tradeoff |
|---|---|---|---|---|
| Wegovy pill | Oral semaglutide 25 mg | First oral GLP-1 weight-loss semaglutide option | About 16.6% if all stayed on treatment in OASIS 4 | Must be taken correctly around fasting and water rules |
| Foundayo | Orforglipron | Small-molecule GLP-1 pill with no food or water restrictions | 12.4% at highest dose in ATTAIN-1 | Lower average weight loss than top injections |
If a person hates injections, the best GLP-1 for weight loss may be oral even if the average number is lower. A medication that someone will actually take for a year can beat a stronger injection they avoid, skip, or stop.
Between the two oral options, Wegovy pill has the stronger weight-loss headline. Foundayo has the easier routine. That split is exactly why “best” cannot be answered by one number alone.
What About Ozempic and Mounjaro?
The brand names confuse everything.
Ozempic and Mounjaro are diabetes brands. Wegovy and Zepbound are weight-management brands. The active ingredients overlap:
| Active Ingredient | Diabetes Brand | Weight-Management Brand | What Searchers Should Know |
|---|---|---|---|
| Semaglutide | Ozempic / Rybelsus | Wegovy / Wegovy HD / Wegovy pill | Same core molecule, different dose and label context |
| Tirzepatide | Mounjaro | Zepbound | Same core molecule, weight-loss brand is Zepbound |
| Liraglutide | Victoza | Saxenda | Older daily GLP-1 with lower average weight loss |
That distinction matters for insurance, pharmacy availability, dosing, and medical documentation. Someone may say they are taking “Ozempic for weight loss,” but the obesity-labeled semaglutide product is Wegovy.
Where Saxenda Fits Now
Saxenda is the older fallback.
Saxenda is liraglutide 3 mg, a once-daily GLP-1 injection. It helped create the modern GLP-1 weight-loss category, but it is no longer the top choice for average weight loss.
In a large weight-management trial, liraglutide 3 mg produced about 8% average body-weight loss after 56 weeks. That is meaningful, but it trails Wegovy, Wegovy HD, and Zepbound. Daily injections also make it harder to stay consistent than weekly injections or pills.
Saxenda can still make sense when a clinician prefers it, when coverage is better, when a patient has a specific history with liraglutide, or when other options are unavailable. It should not be presented as the best average-results option in 2026.
Best GLP-1 by Situation
The best fit changes fast.
| Situation | Best Starting Conversation | Why | Watchout |
|---|---|---|---|
| Maximum average weight loss | Zepbound | Best direct head-to-head evidence | Coverage and side effects can limit use |
| Strong semaglutide response | Wegovy HD | Higher-dose semaglutide may narrow the gap | Newer dose, limited real-world experience |
| Needle-free semaglutide | Wegovy pill | Strong oral semaglutide data | Strict administration routine |
| Easiest pill routine | Foundayo | No food or water timing restrictions | Lower average loss than top injections |
| Established single-agonist GLP-1 | Wegovy 2.4 mg | Longer track record and broad recognition | Less average loss than Zepbound |
| Daily GLP-1 option | Saxenda | Older option with pediatric and coverage niches | Daily injection and lower weight loss |
| Diabetes plus weight loss | Mounjaro or Ozempic conversation | Diabetes labels and glucose goals may drive choice | Obesity-label coverage differs |
This is the missing piece in many top-ranking articles. They rank by average loss, then ignore the reasons people quit: nausea, cost, supply, injection anxiety, dose escalation, constipation, and the feeling that eating enough protein becomes a chore.
Side Effects Comparison
The stomach is usually first.
Most GLP-1 side effects cluster around digestion because these medications reduce appetite, slow gastric emptying, and change meal tolerance. Side effects are usually strongest during dose escalation or after a dose jump.
| Side Effect | What It Feels Like | Often Worse With | What Usually Helps |
|---|---|---|---|
| Nausea | Queasy, early fullness, food aversion | Fast titration, large meals, greasy foods | Smaller meals, slower escalation, hydration |
| Constipation | Slow bowels, bloating, pressure | Low fluids, low fiber, low food intake | Fluids, fiber adjustment, movement, clinician guidance |
| Diarrhea | Urgent or loose stools | Rich meals, dose increases | Simple meals and medical review if persistent |
| Vomiting | Cannot keep food or fluids down | Overeating past fullness, dose too high | Stop escalation and contact a clinician |
| Reflux | Burning, burping, pressure | Late meals, fatty meals, large portions | Smaller meals and staying upright after eating |
| Muscle loss risk | Strength drops, softer look, fatigue | Too little protein and no resistance training | Protein targets and lifting plan |
Serious warning signs need urgent medical review: severe abdominal pain, repeated vomiting, dehydration, fainting, severe allergic symptoms, vision changes, gallbladder-type pain, or symptoms that feel out of proportion to normal dose-adjustment nausea.
Muscle Loss and “Ozempic Face”
Fast loss has tradeoffs.
People often ask about loose skin, facial volume loss, and muscle loss. The medication is not melting the face directly. Rapid fat loss can make existing facial volume loss more visible, especially when protein intake, resistance training, and sleep are weak.
The same issue applies to lean mass. Any meaningful weight loss can include some lean mass loss. The goal is not zero lean loss. The goal is protecting strength while fat mass drops.
- Use a protein target your clinician or dietitian agrees with.
- Lift weights two to four times weekly if cleared to train.
- Do not let nausea push calories extremely low for weeks.
- Slow dose escalation if eating becomes too difficult.
- Track waist, strength, energy, and photos, not only scale weight.
Cost and Insurance
Access can beat efficacy.
A medication with a better trial result is not better if a person cannot get it, cannot afford it, or has to stop after one month. Top-ranking pages spend a lot of time on cost because that is exactly where real decisions happen.
| Cost Factor | What It Changes | Practical Question |
|---|---|---|
| Insurance diagnosis rules | Whether obesity-label drugs are covered | Does the plan cover weight management or only diabetes? |
| Prior authorization | Delays and denials | What BMI, comorbidity, or step-therapy proof is required? |
| Cash-pay programs | Monthly affordability | Is there a manufacturer savings option or direct-pay path? |
| Supply | Continuity | Can the pharmacy reliably fill the dose you need? |
| Oral vs injection | Adherence | Will you take a daily pill correctly or prefer weekly dosing? |
For a deeper cash-pay breakdown, see our GLP-1 without insurance guide. If you want the broad mechanism overview first, read what GLP-1 means.
Switching Between GLP-1s
Switching is not dose matching.
One of the biggest errors online is treating GLP-1 medications like interchangeable milligrams. They are not. Semaglutide, tirzepatide, liraglutide, and orforglipron have different half-lives, dose ladders, tolerability patterns, and administration rules.
When switching, clinicians usually care about four things: the last dose taken, current side effects, how much weight has already been lost, and why the switch is happening. A switch caused by nausea is different from a switch caused by insurance. A switch from Wegovy 2.4 mg to Zepbound is different from a switch from an injectable to Foundayo.
Switching rule
Do not convert doses by internet charts. There is no universal dose-equivalence table. A safer switch usually starts with the new medication’s escalation logic and adjusts based on tolerance.
Retatrutide and Next-Generation Options
The pipeline is moving fast.
Retatrutide is a triple agonist that targets GIP, GLP-1, and glucagon receptors. It is one reason the “best GLP-1” conversation keeps changing. In phase 2 obesity data, higher-dose retatrutide produced large average weight-loss results, and later-stage programs are designed to test whether that advantage holds.
But retatrutide is not a routine prescription weight-loss option as of May 1, 2026. It belongs in the “watch next” category, not the top rank for someone trying to choose an available medication today.
For deeper comparisons, see retatrutide vs Mounjaro, retatrutide dosing schedule, and amycretin.
How to Choose With Your Clinician
Start with the constraint.
Most people ask, “Which works best?” A better first question is, “What would make me stop?” The answer usually reveals the right starting point.
| Your Main Constraint | Likely Better Conversation | Why |
|---|---|---|
| I want maximum loss | Zepbound first | Best direct comparison evidence |
| I want semaglutide but stronger | Wegovy HD | Higher-dose semaglutide option |
| I hate injections | Wegovy pill or Foundayo | Oral options may improve adherence |
| I have bad nausea history | Slower titration, maybe less aggressive option | Tolerability decides persistence |
| Insurance is strict | Covered brand first | A covered medication beats an ideal one you cannot fill |
| I have type 2 diabetes | Diabetes-labeled options may matter | Glucose control and label coverage can guide selection |
| I am losing strength | Nutrition and training review before dose increase | More appetite suppression may worsen lean-mass loss |
Final Verdict
Zepbound wins the main question.
If the only question is average weight loss from the best proven GLP-1-style medication, Zepbound ranks first. It has the strongest direct comparison against semaglutide and a clear advantage in larger weight-loss thresholds.
But the best real-world medication is the one a patient can access, tolerate, afford, and stay on while eating enough protein and maintaining muscle. Wegovy HD is the most important update for semaglutide users. Wegovy pill and Foundayo are the biggest adherence updates for people who do not want injections. Saxenda is now more of a fallback than a front-runner.
That is the practical ranking: Zepbound for maximum proven loss, Wegovy HD for strongest semaglutide, Wegovy 2.4 mg for established single-agonist care, oral Wegovy or Foundayo for needle-free treatment, and Saxenda only when its specific fit outweighs its weaker average results.
Frequently Asked Questions
Sources
- Aronne et al., SURMOUNT-5: tirzepatide compared with semaglutide for obesity
- FDA: Zepbound approval for chronic weight management
- FDA: Wegovy HD 7.2 mg approval, March 19, 2026
- FDA: Foundayo/orforglipron approval, April 1, 2026
- FDA label: Wegovy tablets, oral semaglutide 25 mg
- Wilding et al., STEP 1 semaglutide 2.4 mg trial
- Pi-Sunyer et al., liraglutide 3 mg weight-management trial
- Eli Lilly: ATTAIN-1 orforglipron weight-loss results
- WeightWatchers: GLP-1 option comparison
- U.S. News: GLP-1 weight loss medication consumer guide